NCT01288092View on ClinicalTrials.gov

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2012

Primary Completion Date

September 30, 2015

Conditions
Metastatic Breast Cancer
Interventions
DRUG

BEZ235

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY